Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection - PubMed (original) (raw)
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
D A Price et al. Proc Natl Acad Sci U S A. 1997.
Abstract
Cytotoxic T lymphocytes (CTLs) are thought to play a crucial role in the termination of the acute primary HIV-1 syndrome, but clear evidence for this presumption has been lacking. Here we demonstrate positive selection of HIV-1 proviral sequences encoding variants within a CTL epitope in Nef, a gene product critical for viral pathogenicity, during and after seroconversion. These positively selected HIV-1 variants carried epitope sequence changes that either diminished or escaped CTL recognition. Other proviruses had mutations that abolished the Nef epitope altogether. These results provide clear evidence that CTLs exert selection pressure on the viral population in acute HIV-1 infection.
Figures
Figure 1
Recognition of CTL epitopes by donor SC2 bulk cultured lymphocytes. (a) HLA B8 Nef (FLKEKGGL) response (Nov. 3, 1995). (b and c) HLA B8 p17-3 Gag (GGKKKYKL) response (Oct. 19, 1995). Screening peptides used were: GGKKKYKL (p17-3 Gag; ref. 13), GEIYKRWII (p24-13 Gag; ref. 13), DCKTILKAL (p24-20 Gag; ref. 13), GPKVKQWPL (Pol; ref. 14), and FLKEKGGL (Nef; P.J.R.G., unpublished work).
Figure 2
Proviral sequence variation in HIV-1 epitopes from SC2. (a) HLA B8 Nef. (b) HLA B8 p17-3 Gag. Variant residues are highlighted.
Figure 3
Nucleotide and amino acid sequence variation in the region of Nef containing the HLA B8 epitope. For donor SC2, a number of clones from each time point (19 from each of the first three time points, 18 from the fourth time point) were sequenced further to incorporate regions flanking the epitope (nucleotides 114–395, amino acids 38–132, numbered according to the nef reference sequence HIV-LAI). (a) The Kabat–Wu index (KWI), calculated at each amino acid position as the number of different residues/frequency of the commonest residue, provides a measure of variability; an index of 1 indicates that no variation was detected at the relevant position (15). The HLA B8 epitope (amino acids 90–97) is shaded. (b) The rates of nonsynonymous (dN) and synonymous (dS) nucleotide substitutions were calculated in a sliding window of 60 nt over all pairwise comparisons between clones at a given time point, according to the method of Nei and Gojobori (16). The window is advanced in steps of three nucleotides, and the values of dN and dS are plotted against the central nucleotide in the window. dN rises sharply at the border of the region encoding the HLA B8 epitope, and exceeds dS over this region. The apparent extension of positive selection beyond the limits of the epitope reflects window width, not flanking mutations. Dotted line, synonymous substitutions; solid line, nonsynonymous substitutions.
Figure 4
(a) Altered recognition of variant Nef epitopes by donor SC2 CTLs. 51Cr-labeled HLA B8-matched targets were added directly to 96-well plates containing peptide, and therefore peptide was present at the concentrations drawn for the duration of the assay. Targets and peptide were incubated at room temperature for 15 min before the addition of effector cells. (b) Functional HLA binding assay. Target cells pulsed with variant peptides containing mutations at position 5 (a HLA B8 anchor position) were not recognized by donor SC2 CTLs after 6 h (N5 and E5) and 10 h (Q5), suggesting that these peptides bind poorly and have high off-rates. (c) The p17-3 Gag Q5 variant is poorly recognized by donor SC2-derived GGKKKYKL-specific CTLs.
Figure 5
Truncations and frameshifts within donor SC2 nef clones (deduced amino acid sequence). Identical single nucleotide deletions (clone 2/17, clone 4/19) resulting in premature termination of the open reading frame 6 aa before the B8 epitope are present at two separate time points, suggesting proviral replicative capacity. Index refers to proviral sequence from 19/10/95. ∗, Stop codon. Shading denotes the epitope. These sequences were not included in either the Kabat–Wu or dN/dS analyses.
Similar articles
- A long-term follow-up of an HIV type 1-infected patient reveals a coincidence of Nef-directed cytotoxic T lymphocyte effectors and high incidence of epitope-deleted variants.
Singh MK, Janvier G, Calvez V, Coulaud P, Rivière Y. Singh MK, et al. AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1265-71. doi: 10.1089/088922201750461320. AIDS Res Hum Retroviruses. 2001. PMID: 11559426 - Altering effects of antigenic variations in HIV-1 on antiviral effectiveness of HIV-specific CTLs.
Ueno T, Idegami Y, Motozono C, Oka S, Takiguchi M. Ueno T, et al. J Immunol. 2007 May 1;178(9):5513-23. doi: 10.4049/jimmunol.178.9.5513. J Immunol. 2007. PMID: 17442933 - Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK, Leandersson AC, Devito C, Kohleisen B, Erfle V, Achour A, Levi M, Schwartz S, Kärre K, Wahren B, Hinkula J. Sandberg JK, et al. Virology. 2000 Jul 20;273(1):112-9. doi: 10.1006/viro.2000.0360. Virology. 2000. PMID: 10891413 - Cytotoxic T lymphocytes in human immunodeficiency virus infection: regulator genes.
Riviere Y, Robertson MN, Buseyne F. Riviere Y, et al. Curr Top Microbiol Immunol. 1994;189:65-74. doi: 10.1007/978-3-642-78530-6_4. Curr Top Microbiol Immunol. 1994. PMID: 7924437 Review. No abstract available.
Cited by
- Immunotoxin-mediated depletion of Gag-specific CD8+ T cells undermines natural control of SIV.
Simpson J, Starke CE, Ortiz AM, Ransier A, Darko S, Llewellyn-Lacey S, Fennessey CM, Keele BF, Douek DC, Price DA, Brenchley JM. Simpson J, et al. JCI Insight. 2024 Jun 17;9(14):e174168. doi: 10.1172/jci.insight.174168. JCI Insight. 2024. PMID: 38885329 Free PMC article. - Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation.
Xu ZM, Gnouamozi GE, Rüeger S, Shea PR, Buti M, Chan HL, Marcellin P, Lawless D, Naret O, Zeller M, Schneuing A, Scheck A, Junier T, Moradpour D, Podlaha O, Suri V, Gaggar A, Subramanian M, Correia B, Gfeller D, Urban S, Fellay J. Xu ZM, et al. Am J Hum Genet. 2024 Jun 6;111(6):1018-1034. doi: 10.1016/j.ajhg.2024.04.013. Epub 2024 May 14. Am J Hum Genet. 2024. PMID: 38749427 Free PMC article. - A binary trait model reveals the fitness effects of HIV-1 escape from T cell responses.
Gao Y, Barton JP. Gao Y, et al. bioRxiv [Preprint]. 2024 Oct 6:2024.03.03.583183. doi: 10.1101/2024.03.03.583183. bioRxiv. 2024. PMID: 38464239 Free PMC article. Preprint. No abstract available. - Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope.
Dolton G, Rius C, Hasan MS, Wall A, Szomolay B, Behiry E, Whalley T, Southgate J, Fuller A; COVID-19 Genomics UK (COG-UK) consortium; Morin T, Topley K, Tan LR, Goulder PJR, Spiller OB, Rizkallah PJ, Jones LC, Connor TR, Sewell AK. Dolton G, et al. Cell. 2022 Aug 4;185(16):2936-2951.e19. doi: 10.1016/j.cell.2022.07.002. Epub 2022 Jul 14. Cell. 2022. PMID: 35931021 Free PMC article. - The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines.
Harris JE. Harris JE. Health Policy Technol. 2022 Jun;11(2):100619. doi: 10.1016/j.hlpt.2022.100619. Epub 2022 Mar 21. Health Policy Technol. 2022. PMID: 35340773 Free PMC article.
References
- Piatak M, Saag M S, Yang L C, Clark S J, Kappes J C, Luk K-C, Hahn B H, Shaw G M, Lifson J D. Science. 1993;259:1749–1754. - PubMed
- Clark S J, Saag M S, Decker W D, Campbell-Hill S, Roberson J L, Veldkamp P J, Kappes J C, Hahn B H, Shaw G M. N Engl J Med. 1991;324:954–960. - PubMed
- Daar E S, Moudgil T, Meyer R D, Ho D D. N Engl J Med. 1991;324:961–964. - PubMed
- Wei X, Ghosh S K, Taylor M E, Johnson V A, Emini E A, Deutsch P, Lifson J D, Bonhoeffer S, Nowak M, Hahn B H, Saag M S, Shaw G M. Nature (London) 1995;373:117–122. - PubMed
- Ho D D, Neumann A U, Perelson A S, Chen W, Leonard J M, Markowitz M. Nature (London) 1995;373:123–126. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical